UK markets close in 43 minutes

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.60+0.01 (+0.06%)
As of 10:46AM EST. Market open.

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
https://www.morphosys.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees544

Key executives

NameTitlePayExercisedYear born
Dr. Jean-Paul Kress M.D.Chairman of Management Board, MD & CEO2.18MN/A1965
Dr. Lucinda Crabtree Ph.D.CFO & Member of Management BoardN/AN/A1979
Ms. Charlotte LohmannChief Legal and Human Resources Officer & Member of Management BoardN/AN/A1970
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Dr. Margit UrbanHead of Discovery Alliances & TechnologiesN/AN/AN/A
Dr. Julia Neugebauer Ph.D.Head of Investor RelationsN/AN/AN/A
Dr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerN/AN/AN/A
Dr. Günter WellnhoferHead of Technical OperationsN/AN/AN/A
Dr. Ralf OstendorpHead of Protein Sciences & CMCN/AN/AN/A
Dr. Harald WatzkaHead of Alliance ManagementN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Corporate governance

MorphoSys AG’s ISS governance QualityScore as of 1 February 2024 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.